Glow-in-the-Dark drug could help brain cancer surgery
NCT ID NCT06417281
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This completed Phase III trial tested a drug called 5-aminolevulinic acid (5-ALA) in 86 adults with malignant brain glioma. Patients took the drug orally before surgery, causing tumor cells to glow under a special light. This helps surgeons see and remove more cancerous tissue. The study focused on how accurately the glowing areas matched actual tumor cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
5-aminolevulinic acid (5-ALA)
What this could lead to
If successful, this could improve surgeons' ability to see and remove more tumor tissue during brain cancer surgery, potentially leading to better outcomes.
What could go wrong
This is a completed Phase III trial with 86 participants, so results are limited in size. The approach only helps visualize tumor tissue and does not cure the disease. Risks include skin sensitivity to light and allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT GLIOMA OF BRAIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huashan Hospital, Fudan University
Shanghai, China